Description:
Zopolrestat is an inhibitor of Aldose Reductase(AR). It has been shown to play roles in inflammation and cancer. It is used for the treatment of diabetic nephropathy and cardiac disease. It was developed by Pfizer and was terminated in clinic phase 2 trials.
- Molecular Weight:419.38
- Boiling Point:598.7±60.0 °C | Condition: Press: 760 Torr
- Melting Point:197-198 °C
- Purity:95%
Molecular Formula:
C19H12F3N3O3S
Canonical SMILES:
C1=CC=C2C(=C1)C(=NN(C2=O)CC3=NC4=C(S3)C=CC(=C4)C(F)(F)F)CC(=O)O
InChI:
InChI=1S/C19H12F3N3O3S/c20-19(21,22)10-5-6-15-14(7-10)23-16(29-15)9-25-18(28)12-4-2-1-3-11(12)13(24-25)8-17(26)27/h1-7H,8-9H2,(H,26,27)
InChIKey:
BCSVCWVQNOXFGL-UHFFFAOYSA-N
Solubility:
DMSO: ≥20 mg/mL
Appearance:
Off white to light brown powder
Application:
Zopolrestat is used for the treatment of diabetic nephropathy and cardiac disease.
Storage: 2-8ºC
Synonyms:
3-[(5-Trifluoromethyl-2-benzothiazolyl)methyl]-3,4-dihydro-4-oxophthalazine-1-acetic acid;CP-73850;3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid;Alond;Xedia;2-[4-Oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]phthalazin-1-yl]acetic acid;CP 73850; CP73850; CP-73850; Zopolrestat; Zopolrestatum Weitere Informationen finden Sie
hier